ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

Also called NCT07371689

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07371689
  • EU CT 2025-521478-32-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07371689. Randomized; quadruple masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS
Acronym
ANAPEM
Condition
PEDIATRIC ACUTE MYOCARDITIS
Intervention (Drug)
Anakinra, KINERET®
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct07371689
Content hash
2625840336a392936866c2c62b95b42494961b19216805fda475b11c06720225